Björn Rüter

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

Michael Lübbert, Stefan Suciu, Liliana Baila et al. · Journal of Clinical Oncology · 2011 · 546 citations · Full text

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

Michael Lübbert, Björn Rüter, Rainer Claus et al. · Haematologica · 2011 · 230 citations · Full text

Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)

P. Wijermans, Björn Rüter, Maria R. Baer et al. · Leukemia Research · 2007 · 124 citations

Hematological Malignancy, Oncology, Chronic Myelomonocytic Leukemia +7

Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting

Michael Lübbert, Hartmut Bertz, Ralph Wäsch et al. · Bone Marrow Transplantation · 2009 · 98 citations

Hematological Malignancy, Transplantation, Older Patients +10

Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients

Michael Lübbert, Hartmut Bertz, Björn Rüter et al. · Bone Marrow Transplantation · 2009 · 89 citations

Older Mds/aml Patients, Therapeutic Drug Monitoring, Medicine +7